Payment overview · 2025
General Payments
$2,003.67
99 reported records · 22 companies
Healthcare provider profile · identity verified
Kellen H Gower, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BROOKSVILLE, FL · NPI 1356796601
Verified facts
What the public records show
CMS Open Payments records show Kellen H Gower, M.D. received $2,003.67 in general payments during 2025 across 99 reported records.
Novo Nordisk Inc accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $377.14 | 18.8% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $226.36 | 11.3% | 10 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $225.86 | 11.3% | 13 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $198.40 | 9.9% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $195.84 | 9.8% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $125.98 | 6.3% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $123.25 | 6.2% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $91.30 | 4.6% | 5 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $76.26 | 3.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $65.19 | 3.2% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.85 | 1.9% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.71 | 1.6% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.18 | 1.4% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.93 | 1.4% | 1 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $27.08 | 1.4% | 1 | 2025 |
| Telix Pharmaceuticals | Unresolved — no canonical attribution shown | $25.19 | 1.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.64 | 1.2% | 1 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $22.90 | 1.1% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.21 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.26 | 1.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.23 | 0.9% | 1 | 2025 |
| Fidia Pharma USA Inc. | Unresolved — no canonical attribution shown | $14.91 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,003.67 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $261.80 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $198.40 | 13 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $197.90 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $180.15 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $147.91 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $147.91 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $125.98 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $123.25 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $115.34 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $111.93 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $111.93 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $92.21 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $87.17 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $83.91 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.66 | 4 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $76.26 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $65.19 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $64.45 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $46.98 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $38.85 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.71 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.93 | 1 | 2025 |
Source payment records
|
|||||
| DUROLANE Normalized: durolane |
Device | Bioventus LLC | $27.08 | 1 | 2025 |
Source payment records
|
|||||
| ILLUCCIX Normalized: illuccix |
Drug | Telix Pharmaceuticals | $25.19 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.23 | 1 | 2025 |
Source payment records
|
|||||
| HYMOVIS Normalized: hymovis |
Device | Fidia Pharma USA Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| TRILURON Normalized: triluron |
Device | Fidia Pharma USA Inc. | $14.91 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.64 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 135 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 147 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 16 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
135 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 656 | 209 |
| Atorvastatin Calcium | Atorvastatin Calcium | 613 | 191 |
| Losartan Potassium | Losartan Potassium | 476 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 453 | 124 |
| Alprazolam | Alprazolam | 386 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 320 | 112 |
| Pantoprazole Sodium | Pantoprazole Sodium | 311 | 95 |
| Lisinopril | Lisinopril | 310 | 102 |
| Omeprazole | Omeprazole | 286 | 87 |
| Tramadol Hcl | Tramadol Hcl | 276 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 264 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 237 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 215 | 71 |
| Metformin Hcl | Metformin Hcl | 214 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 205 | 66 |
| Famotidine | Famotidine | 199 | 75 |
| Furosemide | Furosemide | 193 | 63 |
| Trazodone Hcl | Trazodone Hcl | 176 | 58 |
| Simvastatin | Simvastatin | 175 | 49 |
| Gabapentin | Gabapentin | 172 | 63 |
| Zolpidem Tartrate | Zolpidem Tartrate | 168 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 164 | 54 |
| Carvedilol | Carvedilol | 160 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 50 |
| Meloxicam | Meloxicam | 150 | 50 |
| Jardiance | Empagliflozin | 147 | 36 |
| Lorazepam | Lorazepam | 143 | 24 |
| Alendronate Sodium | Alendronate Sodium | 139 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 48 |
| Pregabalin | Pregabalin | 137 | 31 |
| Eliquis | Apixaban | 135 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 127 | 45 |
| Diclofenac Sodium | Diclofenac Sodium | 125 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 122 | 34 |
| Fluconazole | Fluconazole | 122 | 72 |
| Sertraline Hcl | Sertraline Hcl | 121 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 120 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 34 |
| Clonazepam | Clonazepam | 111 | 15 |
| Potassium Chloride | Potassium Chloride | 109 | 37 |
| Allopurinol | Allopurinol | 106 | 28 |
| Glipizide Er | Glipizide | 106 | 39 |
| Montelukast Sodium | Montelukast Sodium | 96 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 90 | 17 |
| Ondansetron Odt | Ondansetron | 88 | 36 |
| Ezetimibe | Ezetimibe | 87 | 31 |
| Methylprednisolone | Methylprednisolone | 87 | 71 |
| Metformin Hcl Er | Metformin Hcl | 86 | 27 |
| Ozempic | Semaglutide | 85 | 20 |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 82 | 17 |
| Atenolol | Atenolol | 80 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 74 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 38 |
| Baclofen | Baclofen | 73 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 21 |
| Chlorthalidone | Chlorthalidone | 70 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 68 | 20 |
| Xarelto | Rivaroxaban | 67 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 65 | 11 |
| Synthroid | Levothyroxine Sodium | 64 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 18 |
| Sucralfate | Sucralfate | 62 | 26 |
| Azithromycin | Azithromycin | 61 | 51 |
| Celecoxib | Celecoxib | 61 | 18 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 59 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 54 | 18 |
| Temazepam | Temazepam | 54 | suppressed |
| Glimepiride | Glimepiride | 52 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 52 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Prednisone | Prednisone | 51 | 25 |
| Finasteride | Finasteride | 50 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 50 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 16 |
| Spironolactone | Spironolactone | 50 | 19 |
| Farxiga | Dapagliflozin Propanediol | 48 | suppressed |
| Repatha Sureclick | Evolocumab | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 15 |
| Diazepam | Diazepam | 47 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 44 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | 11 |
| Mirtazapine | Mirtazapine | 43 | 14 |
| Valacyclovir | Valacyclovir Hcl | 43 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | 14 |
| Buspirone Hcl | Buspirone Hcl | 41 | 14 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Naproxen | Naproxen | 40 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 40 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 40 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Primidone | Primidone | 38 | suppressed |
| Ketoconazole | Ketoconazole | 36 | 19 |
| Propranolol Hcl | Propranolol Hcl | 35 | 13 |
| Candesartan Cilexetil | Candesartan Cilexetil | 34 | suppressed |
| Colchicine | Colchicine | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | 11 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | 12 |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 31 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 21 |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Glipizide | Glipizide | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 21 |
| Nitroglycerin | Nitroglycerin | 28 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 25 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 23 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 17 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 20 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 19 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Nystatin | Nystatin | 18 | 11 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Humulin R | Insulin Regular, Human | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 14 | suppressed |
| Dutasteride | Dutasteride | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Topiramate Er | Topiramate | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,003.67 · 99 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, Azstarys, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, DUROLANE, ELIQUIS, ENTRESTO, FARXIGA, FREESTYLE LIBRE 3, HYMOVIS, ILLUCCIX, JARDIANCE, Jornay PM, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TRILURON, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error